Under the agreement, JFCR will join Parexel’s Global Site Alliance network for oncology clinical trials and providing more opportunities for Japanese patients to participate in cancer research
Parexel and the Japanese Foundation for Cancer Research (JFCR) has announced a strategic alliance to accelerate access to oncology clinical trials in Japan.
Under the agreement, JFCR will join Parexel’s Global Site Alliance network for oncology clinical trials and providing more opportunities for Japanese patients to participate in cancer research. Parexel will leverage JFCR’s expertise to help sponsors develop protocols that better align with Japan’s standard of care and regulatory approval processes — resulting in streamlined patient recruitment and study start-up.
Shigehiro Miki, Parexel Corporate Vice President and General Manager of Japan said,“Consistent with global trends, the incidence of cancer is expected to increase in Japan. We look forward to JFCR joining Parexel’s Site Alliance Network and working together to eliminate barriers and increase the access of potentially life-changing treatments to Japanese patients.”
Takeshi Sano, MD, PhD, FRCS, Hospital Director, Cancer Institute Hospital, JFCR said, “Parexel and JFCR enter into this strategic alliance driven by a shared sense of urgency to enable sponsors to conduct trials in Japan and ensure these patients have access to innovative clinical research. To improve well-being of people worldwide by conquering cancer is the fundamental principle of JFCR. We look forward to collaborating closely with Parexel to realise our principle.”
- Advertisement -